| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The results of this study show that the PD-1 pathway is important in the alleviation of chronic GVHD. Blockade of the PD-1 pathway using anti PD-1, anti PD-L1, or anti PD-L2 mAbs exacerbated chronic GVHD, and chimeric mice showed the importance of PD-L1 expression in host tissues in attenuating chronic GVHD. BMT into PD-L1 deficient recipients revealed IL-17+IFN-gamma+ T cell expansion and Am80 administration of Am80 overcame the IL-17+IFN-gamma+ T cell expansion caused by PD-L1 deficiency, resulting in reduced chronic GVHD damage in PD-L1 deficient recipients. Stimulation of the PD-1 pathway with an agonistic anti PD-1 mAb alleviated chronic GVHD, suggesting a new target for the prevention or treatment of chronic GVHD.
|
